PortfoliosLab logo
SRTS vs. GENE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SRTS and GENE is 0.00. This indicates that the assets' prices tend to move in opposite directions. Negative correlation can be particularly beneficial for diversification and risk management, as one asset may offset the losses of the other during market fluctuations.


Performance

SRTS vs. GENE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sensus Healthcare, Inc. (SRTS) and Genetic Technologies Limited (GENE). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Fundamentals

Market Cap

SRTS:

$74.06M

GENE:

$3.71M

EPS

SRTS:

$0.41

GENE:

-$0.02

PEG Ratio

SRTS:

0.00

GENE:

0.00

PS Ratio

SRTS:

1.77

GENE:

0.38

PB Ratio

SRTS:

1.33

GENE:

3.29

Total Revenue (TTM)

SRTS:

$31.14M

GENE:

$4.80M

Gross Profit (TTM)

SRTS:

$17.77M

GENE:

$2.80M

EBITDA (TTM)

SRTS:

$5.34M

GENE:

-$5.47M

Returns By Period


SRTS

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

GENE

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SRTS vs. GENE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SRTS
The Risk-Adjusted Performance Rank of SRTS is 6363
Overall Rank
The Sharpe Ratio Rank of SRTS is 6262
Sharpe Ratio Rank
The Sortino Ratio Rank of SRTS is 6565
Sortino Ratio Rank
The Omega Ratio Rank of SRTS is 6464
Omega Ratio Rank
The Calmar Ratio Rank of SRTS is 6464
Calmar Ratio Rank
The Martin Ratio Rank of SRTS is 6161
Martin Ratio Rank

GENE
The Risk-Adjusted Performance Rank of GENE is 77
Overall Rank
The Sharpe Ratio Rank of GENE is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of GENE is 44
Sortino Ratio Rank
The Omega Ratio Rank of GENE is 33
Omega Ratio Rank
The Calmar Ratio Rank of GENE is 88
Calmar Ratio Rank
The Martin Ratio Rank of GENE is 1414
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SRTS vs. GENE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Sensus Healthcare, Inc. (SRTS) and Genetic Technologies Limited (GENE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.



Loading data...

Dividends

SRTS vs. GENE - Dividend Comparison

Neither SRTS nor GENE has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SRTS vs. GENE - Drawdown Comparison


Loading data...

Volatility

SRTS vs. GENE - Volatility Comparison


Loading data...

Financials

SRTS vs. GENE - Financials Comparison

This section allows you to compare key financial metrics between Sensus Healthcare, Inc. and Genetic Technologies Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00M4.00M6.00M8.00M10.00M12.00M14.00MAprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
13.07M
4.80M
(SRTS) Total Revenue
(GENE) Total Revenue
Values in USD except per share items